Cancer BiologybioRxivPreprint
Trastuzumab deruxtecan combination strongly enhances responses and overcomes sotorasib resistance in KRASG12C-mutant NSCLC
Hilal Özakıncı, Bina Desai, Denise Kalos…·Bruna Pellini
This study shows that combining trastuzumab deruxtecan with sotorasib improves responses in KRASG12C-mutant NSCLC and overcomes resistance, but HER2 expression levels influence treatment effectiveness.
2 citations